Effect of recombinant human brain natriuretic peptide on patients with non-ST segment elevation acute coronary syndrome

2021 ◽  
Vol 7 (5) ◽  
pp. 3226-3231
Author(s):  
Wubin Wu ◽  
LiZhi Liu ◽  
Jiacai Chen
Keyword(s):  
Acute Coronary Syndrome ◽  
Human Brain ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Control Group ◽  
Study Group ◽  
St Segment Elevation ◽  
Coronary Syndrome ◽  
St Segment ◽  
Elevation Acute Coronary Syndrome

Objective: To investigate the effect of recombinant human brain natriuretic peptide on patients with non-ST segment elevation acute coronary syndrome. Methods: 80 patients with non-ST segment elevation acute coronary syndrome diagnosed and treated in our hospital from January 2017 to December 2019 were randomly divided into study group (n = 41) and control group (n = 39). All patients were treated with basal therapy, the control group was treated with isosorbide dinitrate, and the study group was treated with recombinant human brain natriuretic peptide on the basis of the control group. The changes of cardiac function indexes, renal function indexes and hemodynamic parameters before and after treatment were observed and compared between the two groups. Results: The total effective rate of the study group was 87.80%, which was significantly higher than that of the control group (69.23%) (P<0.05). There was no significant difference in left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD) and left ventricular ejection fraction (LVEF), hemodynamic parameters’ cardiac index (CI), central venous pressure (CVP), mean arterial pressure (MAP), systemic vascular resistance index (SVRI) and glomerular filtration rate (eGFR) between the two groups before treatment (P>0.05). After treatment, LVEDD, LVESD and SVRI were all decreased than that before treatment in the two groups, LVEF, CI, CVP, MAP and eGFR were higher than those before treatment (P<0.05), and LVEDD, LVESD and SVRI in the study group were lower than those in the control group, and LVEF, CI, CVP, MAP and eGFR were higher than those in the control group (P<0.05). Conclusion: Recombinant human brain natriuretic peptide is effective in the treatment of non-ST segment elevation acute coronary syndrome, which is beneficial not only for the recovery of cardiac function, but also for the improvement of hemodynamic staus and renal function.

scholarly journals Analysis of ticagrelor’s cardio-protective effects on patients with ST-segment elevation acute coronary syndrome accompanied with diabetes

Open Medicine ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. 234-240 ◽  
Author(s):  
Dong-Tao Li ◽  
Shun-Bao Li ◽  
Jian-Yong Zheng ◽  
Hai-hong Tang ◽  
Yi-Gang Qiu ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Adverse Reactions ◽  
Left Ventricular ◽  
Control Group ◽  
Observation Group ◽  
Protective Effects ◽  
St Segment Elevation ◽  
Coronary Syndrome ◽  
St Segment ◽  
Elevation Acute Coronary Syndrome

AbstractBackgroundTo analyze the cardio-protective effects of ticagrelor in patients with acute coronary syndrome with S-T segment elevation.MethodsThe sample was 200 patients who had been diagnosed with acute coronary syndrome accompanied by diabetes Mellitus type II. Only patients having ST segment elevation before the treatment were included. Then, the subjects were further randomly divided into an observation group and a control group. The control group of 100 patients received clopidogrel; the observation group of 100 patients of ticagrelor. The serous creatine kinase CK-MB, functional cardiac indexes of left ventricular end diastolic diameter (LVDD), cardiac troponin I, ventricular ejection fraction, and relevant major adverse cardiovascular events (MACE) were compared between the two groups.ResultsOne month after a percutaneous coronary intervention (PCI) the observation group showed better results against angina, stent thrombosis, and all-cause mortality compared with those of the control subjects. Six months after treatment, both groups suffered adverse reactions. The number of patients who suffered adverse reactions in respiratory tract in the observation group was higher than in the control group. The inhibition of platelet aggregation IPA of ticagrelor was found to be significantly higher than clopidogrel, having a significant p value.ConclusionTicagrelor can effectively protect myocardial function for patients with ST-segment elevation acute coronary syndrome accompanied by diabetes and can reduce the incidence of adverse reactions..

Sign in / Sign up

Export Citation Format

Share Document